Sandbox Reserved 1066: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 62: | Line 62: | ||
== Future Research == | == Future Research == | ||
While currently there are no specific drug targets for FadD13, a better understanding of key residues involved in the activation of very-long-chain fatty acids is a promising start to developing new drug targets for ''(M. tb)''. Recent studies have shown the ''mymA'' operon, which is involved in the maintenance of ''(M. tb)'' cell wall architecture, and which codes for the enzyme FadD13, is | While currently there are no specific drug targets for FadD13, a better understanding of key residues involved in the activation of very-long-chain fatty acids is a promising start to developing new drug targets for ''(M. tb)''. Recent studies have shown the ''mymA'' operon, which is involved in the maintenance of ''(M. tb)'' cell wall architecture, and which codes for the enzyme FadD13, is up-regulated under acidic conditions. <ref name="molecular studies"/> Functional loss of the ''mymA'' operon resulted in increased drug sensitivity and death of the pathogen; therefore any drugs that can can target this operon will be effective at fighting tuberculosis. <ref name="molecular studies"/> | ||
</StructureSection> | </StructureSection> | ||
